@entity3524 treatment was evaluated in 41 @entity1 with serious @entity79 . @entity5414 and @entity2585 (8), @entity4432 (33) were treated with 3 to 12 g of @entity3524 per day for three to 52 days. The diagnosis of @entity4034 or @entity5414 was made on the basis of clinical and roentgenographic evidence of @entity281 . The diagnosis of a @entity281 was confirmed by a positive culture of a joint aspirate sample. The diagnosis of a @entity79 was confirmed by either a positive culture of a bone biopsy or of blood in combination with a positive bone scan or roentgenogram. @entity794 was the most frequently isolated pathogen. Overall, 36 of 41 @entity1 , who met all criteria for evaluation, had satisfactory responses to @entity3524 . The drug was well tolerated by all @entity1 . However, six @entity1 had a direct Coomb's test, two @entity1 were noted to be @entity1398 and two @entity1 developed a macular @entity1910 . It is concluded that @entity3524 is a useful and safe antibiotic for the treatment of @entity4034 and @entity5414 .

XXXX caused by gram-positive bacteria: treatment with @entity3524 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1910 :: ('MESH:D005076', 'Disease') :: ['rash'] @entity5414 :: ('MESH:D001170', 'Disease') :: ['septic arthritis', 'Septic arthritis'] @entity4034 :: ('MESH:D010019', 'Disease') :: ['osteomyelitis'] @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus'] @entity3524 :: ('MESH:D002439', 'Chemical') :: ['cefotaxime', 'Cefotaxime'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone and joint infections', 'bone infection'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'joint infection'] @entity4432 :: ('MESH:D065290', 'Disease') :: ['acute and chronic osteomyelitis'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenic'] @entity2585 :: ('MESH:D002062', 'Disease') :: ['bursitis']
@entity79 :: (MESH:D001847,Disease) :: ['Bone and joint infections']
